Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ko, Young-Guk, Kim, Byeong-Keuk, Lee, Byoung Kwon, Kang, Woong Chol, Choi, Seung Hyuk, Kim, Sang Wook, Lee, Jong Ho, Lee, Myoungsook, Honda, Yasuhiro, Fitzerald, Peter J, Shim, Won-Heum
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033833/
https://ncbi.nlm.nih.gov/pubmed/21226953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-12-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados